The Renal Division of OPKO Health, Inc. focuses on developing proprietary products to treat secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). OPKO’s expertise in Vitamin D chemistry, biochemistry, metabolism and physiology, combined with its experience in successfully bringing Vitamin D therapeutics to market uniquely positions the Renal Division to improve the lives of CKD patients. We are proud of our lead nephrology product, Rayaldee® (calcifediol) extended-release capsules, launched in 2016. In addition, the Renal Division is developing novel therapies to treat elevated blood phosphorus levels (hyperphosphatemia) in order to improve the control of SHPT in CKD patients.
Brands: RAYALDEE